Skip to content
Screener

Upstream Bio, Inc. UPB Price / sales

Price / sales at other companies

Amgen logo
AmgenAMGN
5.1×+0.9×
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
4.2×+0.2×
Aclaris Therapeutics logo
Aclaris TherapeuticsACRS
89.9×+80.1×
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
662.8×+646×
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
6.9×+1.8×
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
176.3×+173×

Other financials

Income statement

See full
Revenue$773.0K-17.5%
Operating income-$42.4M+4.5%
Net income-$39.7M+0.7%
EPS (diluted)-$0.73+1.4%

Balance sheet

See full
Cash & equivalents$79.4M+74.7%
Total debt$954.0K-38.9%
Total equity$271.0M-33.7%
Total assets$281.2M-33.1%

Cash flow

See full
Operating cash flow-$35.6M+9.2%
CapEx$54.0K-70.8%
Free cash flow-$30.7M-55.0%

Valuation

See full
Market cap$394.54M-54.7%
Enterprise value$316.1M-61.6%

Profitability

See full
Operating margin-5,382.6%+1,393pp
Net margin-4,955.7%+2,041pp

Returns & leverage

See full
Return on equity-46%—
Debt / equity0×0.0×
Current ratio28×-10.3×

Where this comes from

Calculated from Upstream Bio, Inc.’s reported figures.

market cap/total revenue=119.2×

Based on the most recent quarter.

The source filing: Upstream Bio, Inc.’s 10-Q, filed August 11, 2026. Open the filing →

Filed
Aug 11, 2026, 7:10 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-343417

FAQ

What is Upstream Bio, Inc.'s price / sales?
Upstream Bio, Inc. (UPB) reported price / sales of 119.2× in Q2 2026.
How has Upstream Bio, Inc.'s price / sales changed year-over-year?
Upstream Bio, Inc.'s price / sales decreased by 47.0% year-over-year, from 225× to 119.2×.
What does price / sales mean?
Market capitalization at the quarter end divided by trailing-twelve-month revenue. The price the market pays for each dollar of sales.

Ask your AI about Upstream Bio, Inc.'s price / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude